Tumor budding as a prognostic criterion of colorectal cancer

Authors

DOI:

https://doi.org/10.14739/2310-1237.2021.3.233555

Keywords:

tumor budding, colorectal cancer, recurrence, prognosis

Abstract

Colorectal cancer (CRC) is the second leading cause of mortality among cancers after malignant tumors of respiratory system. One of the most significant prognostic features of CRC is tumor budding (TB), which isn’t widely implemented in clinical practice.

The aim of this research: to find the prognostic criteria of recurrence and lethal outcome of CRR IIA and IIIB stages (рТ3N0-2M0), the ratio of tumors with certain differentiation in groups of research was taken equal.

Material and methods. The group I was formed from primary CRC without recurrences. The main relapse-free survival time was 5 years (62.5 ± 16.5 months). The ІІ group – primary CRC with recurrences; ІІА – with recurrences during 5 years from the moment when the tumor was removed, without fatal outcome; ІІВ – with recurrences and lethal outcome from genera­lization of tumor process during 5 years from the moment when the tumor was removed. The microslides of CRC were made by using the standard methods.

Results. TB was identified in 46.66 % (28/60) of CRC рТ3N0-2M0. The direct relationship between tumor grade and presence of TB was found (Р < 0.05), but TB didn’t define differentiation of the CRC. There was a statistically significant relationship between TB and metastatic spreading of CRC to regional lymph nodes (Р < 0.001). Metastasis was associated with 3 stage of TB, absence of metastasis was typical for CRC without TB.

The tendency was found in a larger number of cases of the CRC with TB 3 stage among recurring CRC compared with CRC without recurrence, mainly due to the ІІВ group of the research. Inverse correlation between TB stage and time of recurrence appearance was found (Р < 0.05). TB in central tumor sites was followed by presence and higher stage of TB in peripheral tumor sites (Р < 0.05), that can be taken into account during biopsies of CRC.

Conclusions. TB is a prognostic criterion of metastasis and time of recurrence appearance for CRC рТ3N0-2M0, which is mostly typical for tumors in patients with recurrences and lethal outcome at the taken equal ratio of tumors by differen­tiation.

Author Biographies

I. I. Yakovtsova, Kharkiv Medical Academy of Postgraduate Education, Ukraine

MD, PhD, DSc, Professor, Head of the Department of Pathological Anatomy

V. M. Cheverda, Kharkiv National Medical University, Ukraine

MD, PhD, DSc, Professor of the Department of Surgery No. 2

O. V. Dolhaia, Kharkiv Medical Academy of Postgraduate Education, Ukraine

MD, PhD, Associate Professor of the Department of Pathological Anatomy

A. S. Yakymenko, V. N. Karazin Kharkiv National University, Ukraine

Assistant of the Department of General and Clinical Pathology

I. V. Ivakhno, Kharkiv Medical Academy of Postgraduate Education, Ukraine

MD, PhD, Assistant of the Department of Pathological Anatomy

References

Mattiuzzi, C., Sanchis-Gomar, F., & Lippi, G. (2019). Concise update on colorectal cancer epidemiology. Annals of translational medicine, 7(21), 609. https://doi.org/10.21037/atm.2019.07.91

Poornakala, S., & Prema, N. S. (2019). A study of morphological prognostic factors in colorectal cancer and survival analysis. Indian journal of pathology & microbiology, 62(1), 36-42. https://doi.org/10.4103/IJPM.IJPM_91_18

Konishi, T., Shimada, Y., Lee, L. H., Cavalcanti, M. S., Hsu, M., Smith, J. J., Nash, G. M., Temple, L. K., Guillem, J. G., Paty, P. B., Garcia-Aguilar, J., Vakiani, E., Gonen, M., Shia, J., & Weiser, M. R. (2018). Poorly Differentiated Clusters Predict Colon Cancer Recurrence: An In-Depth Comparative Analysis of Invasive-Front Prognostic Markers. The American journal of surgical pathology, 42(6), 705-714. https://doi.org/10.1097/PAS.0000000000001059

Guo, T. A., Wu, Y. C., Tan, C., Jin, Y. T., Sheng, W. Q., Cai, S. J., Liu, F. Q., & Xu, Y. (2019). Clinicopathologic features and prognostic value of KRAS, NRAS and BRAF mutations and DNA mismatch repair status: A single-center retrospective study of 1,834 Chinese patients with Stage I-IV colorectal cancer. International journal of cancer, 145(6), 1625-1634. https://doi.org/10.1002/ijc.32489

Lugli, A., Kirsch, R., Ajioka, Y., Bosman, F., Cathomas, G., Dawson, H., El Zimaity, H., Fléjou, J. F., Hansen, T. P., Hartmann, A., Kakar, S., Langner, C., Nagtegaal, I., Puppa, G., Riddell, R., Ristimäki, A., Sheahan, K., Smyrk, T., Sugihara, K., Terris, B., … Quirke, P. (2017). Recommendations for reporting tumor budding in colorectal cancer based on the International Tumor Budding Consensus Conference (ITBCC) 2016. Modern pathology, 30(9), 1299-1311. https://doi.org/10.1038/modpathol.2017.46

Lugli, A., Zlobec, I., Berger, M. D., Kirsch, R., & Nagtegaal, I. D. (2021). Tumour budding in solid cancers. Nature reviews. Clinical oncology, 18(2), 101-115. https://doi.org/10.1038/s41571-020-0422-y

Nagtegaal, I. D., Odze, R. D., Klimstra, D., Paradis, V., Rugge, M., Schirmacher, P., Washington, K. M., Carneiro, F., Cree, I. A., & WHO Classification of Tumours Editorial Board (2020). The 2019 WHO classification of tumours of the digestive system. Histopathology, 76(2), 182-188. https://doi.org/10.1111/his.13975

Van Wyk, H. C., Roseweir, A., Alexander, P., Park, J. H., Horgan, P. G., McMillan, D. C., & Edwards, J. (2019). The Relationship Between Tumor Budding, Tumor Microenvironment, and Survival in Patients with Primary Operable Colorectal Cancer. Annals of surgical oncology, 26(13), 4397-4404. https://doi.org/10.1245/s10434-019-07931-6

Lino-Silva, L. S., Salcedo-Hernández, R. A., & Gamboa-Domínguez, A. (2018). Tumour budding in rectal cancer. A comprehensive review. Contemporary oncology, 22(2), 61-74. https://doi.org/10.5114/wo.2018.77043

Argilés, G., Tabernero, J., Labianca, R., Hochhauser, D., Salazar, R., Iveson, T., Laurent-Puig, P., Quirke, P., Yoshino, T., Taieb, J., Martinelli, E., Arnold, D., & ESMO Guidelines Committee. Electronic address: clinicalguidelines@esmo.org (2020). Localised colon cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Annals of oncology, 31(10), 1291-1305. https://doi.org/10.1016/j.annonc.2020.06.022

Vogel, J. D., Eskicioglu, C., Weiser, M. R., Feingold, D. L., & Steele, S. R. (2017). The American Society of Colon and Rectal Surgeons Clinical Practice Guidelines for the Treatment of Colon Cancer. Diseases of the colon and rectum, 60(10), 999-1017. https://doi.org/10.1097/DCR.0000000000000926

Grigore, A. D., Jolly, M. K., Jia, D., Farach-Carson, M. C., & Levine, H. (2016). Tumor Budding: The Name is EMT. Partial EMT. Journal of clinical medicine, 5(5), 51. https://doi.org/10.3390/jcm5050051

Giger, O. T., Comtesse, S. C., Lugli, A., Zlobec, I., & Kurrer, M. O. (2012). Intra-tumoral budding in preoperative biopsy specimens predicts lymph node and distant metastasis in patients with colorectal cancer. Modern pathology, 25(7), 1048-1053. https://doi.org/10.1038/modpathol.2012.56

Amin, M. B., Greene, F. L., Edge, S. B., Compton, C. C., Gershenwald, J. E., Brookland, R. K., Meyer, L., Gress, D. M., Byrd, D. R., & Winchester, D. P. (2017). The Eighth Edition AJCC Cancer Staging Manual: Continuing to build a bridge from a population-based to a more "personalized" approach to cancer staging. CA: a cancer journal for clinicians, 67(2), 93-99. https://doi.org/10.3322/caac.21388

Bronsert, P., Enderle-Ammour, K., Bader, M., Timme, S., Kuehs, M., Csanadi, A., Kayser, G., Kohler, I., Bausch, D., Hoeppner, J., Hopt, U. T., Keck, T., Stickeler, E., Passlick, B., Schilling, O., Reiss, C. P., Vashist, Y., Brabletz, T., Berger, J., Lotz, J., … Wellner, U. F. (2014). Cancer cell invasion and EMT marker expression: a three-dimensional study of the human cancer-host interface. The Journal of pathology, 234(3), 410-422. https://doi.org/10.1002/path.4416

Downloads

Published

2021-12-01

How to Cite

1.
Yakovtsova II, Cheverda VM, Dolhaia OV, Yakymenko AS, Ivakhno IV. Tumor budding as a prognostic criterion of colorectal cancer. Pathologia [Internet]. 2021Dec.1 [cited 2024Nov.8];18(3):346-51. Available from: http://pat.zsmu.edu.ua/article/view/233555

Issue

Vol. 18 No. 3 (2021): Pathologia

Section

Original research

License

Authors who publish with this journal agree to the following terms:

    1. Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
Лицензия Creative Commons
    1. Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.

  1. Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (SeeThe Effect of Open Access).